Translational control: a target for cancer therapy.
Cap-mediated translation is the default mechanism for the synthesis of proteins in eukaryotic cells. Increasingly, malignant cells have been found to have deregulation of this process. Return of normal translational control is associated with loss of tumorigenic potential in pre-clinical models. Currently, a variety of novel therapeutics are in development targeting this mechanism as a treatment for cancer.
Thumma
Saritha C
SC
The Division of Hematology-Oncology-Transplant, Department of Medicine, The University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Kratzke
Robert A
RA
D000818:Animals; D039561:Eukaryotic Initiation Factor-4E / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D010442:Peptide Chain Initiation, Translational; D014176:Protein Biosynthesis; D012315:RNA Caps
D039561:Eukaryotic Initiation Factor-4E; D012315:RNA Caps